Study Data On Quality Of Life For Breast Cancer Patients And Survivors, Supported By Napo Pharmaceuticals, Published On San Antonio Breast Cancer Symposium Website
Portfolio Pulse from Benzinga Newsdesk
Napo Pharmaceuticals, part of Jaguar Health, Inc. (NASDAQ:JAGX), announced the availability of an abstract on a Quality of Life survey for cancer patients on the SABCS website. The survey, supported by Napo, highlights the challenges faced by breast cancer patients and survivors, emphasizing the decline in QoL post-cancer. Key concerns include fatigue, muscle/joint pain, and emotional distress. The survey also reveals a lack of preparedness for treatment side effects. Additionally, Jaguar's Phase 3 OnTarget trial for cancer therapy-related diarrhea (CTD) will be presented at SABCS, with results for the drug crofelemer pending.
December 06, 2023 | 1:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jaguar Health's subsidiary, Napo Pharmaceuticals, has published a survey abstract on cancer patient QoL, and will present its Phase 3 OnTarget trial for CTD at SABCS. Positive results from the trial could impact Jaguar's stock positively.
The publication of the survey abstract by Napo Pharmaceuticals and the upcoming presentation of the Phase 3 OnTarget trial results are likely to generate investor interest in Jaguar Health. Positive data from the trial could lead to increased confidence in the company's pipeline and potentially drive the stock price up in the short term. However, the actual impact will depend on the trial results, which are yet to be announced.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80